Organovo

Organovo Holdings, Inc., a biotechnology company, focuses on developing 3D tissues that recapitulate key aspects of human disease. Its 3D human tissue platform includes its proprietary NovoGen Bioprinters, which are automated devices that enable the fabrication of 3D living tissues comprised mammalian cells; and related technologies for preparing bio-inks and bioprinting multicellular tissues with complex architecture. The company offers ExVive human liver tissue and ExVive human kidney tissue used for predictive preclinical testing of drug compounds. The company was incorporated in 2007 and is headquartered in Solana Beach, California.

Organovo's mission is to create 3D bioprinting technology that supports therapies to improve the quality of human life.

Organovo seeks to become a global leader in the development of regenerative medicines by creating living, three-dimensional tissue structures to form the basis of better treatments.

Organovo has been recognized with numerous honors and awards, including being named one of Technology Review's 10 Most Innovative Companies in 2013, and Forbes Magazine's 50 Most Promising Companies of 2014.